Hepion Pharmaceuticals (NASDAQ: HEPA) CEO Gary Stetz submits Form 3

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. director and Chief Executive Officer Gary S. Stetz filed an initial statement of beneficial ownership on Form 3. The filing lists him as both a director and officer of the company but does not report any specific holdings or transactions in this excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Accepted by SEC EDGAR 03/18/2026 - 05:25 PM Learn about SEC filing dates

FAQ

What does the Hepion Pharmaceuticals (HEPA) Form 3 filing by Gary S. Stetz show?

The Form 3 filing records Gary S. Stetz as a director and Chief Executive Officer of Hepion Pharmaceuticals. It is an initial beneficial ownership statement and, in this excerpt, does not list any specific securities holdings or transactions for him.

Who is the reporting person in this Hepion Pharmaceuticals Form 3?

The reporting person is Gary S. Stetz, identified as both a director and an officer of Hepion Pharmaceuticals. His officer title is Chief Executive Officer, and he is not classified as a ten percent owner in this filing excerpt.

Does Gary S. Stetz report any insider transactions in this Hepion Pharmaceuticals Form 3?

No transactions are reported in this Form 3 excerpt. The transactions section is empty, and the transaction summary shows zero buys, sells, exercises, gifts, or other insider trades, indicating this is purely an initial ownership statement record.

Are any derivative securities disclosed for Gary S. Stetz in this Hepion Form 3?

The derivative securities section for Gary S. Stetz is empty in this excerpt. The derivative summary shows zero derivative transactions and no remaining derivative positions, so no options or similar instruments are detailed here for the Hepion CEO.

Is Gary S. Stetz a ten percent owner of Hepion Pharmaceuticals according to this Form 3?

According to the Form 3 data, Gary S. Stetz is not a ten percent owner. The filing flags him as a director and Chief Executive Officer but marks the ten percent owner status as negative in this initial beneficial ownership record.

What does a neutral netBuySellDirection mean in this Hepion Form 3?

A neutral netBuySellDirection indicates there were no reported insider purchases or sales. In this Form 3, all transaction-related counts are zero, reflecting that the filing simply establishes Gary S. Stetz’s reporting status without detailing trading activity.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Stetz Gary S.

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2026

3. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Gary S. Stetz	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)